SCHEMBL16058205

SCHEMBL16058205

CCCCCCCCCc1cccn(C(=O)O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BID P55957 3/20 0.50
▸ MCL1 Q07820 3/20 0.50
▸ PPARA Q07869 3/20 0.50
▸ BCL2L1 Q07817 2/20 0.50
▸ BAK1 Q16611 2/20 0.50
▸ KAT8 Q9H7Z6 2/20 0.50
▸ PPARG P37231 2/20 0.50
▸ SAE1 Q9UBE0 2/20 0.50
▸ EP300 Q09472 1/20 0.50
▸ KAT2A Q92830 1/20 0.50
▸ KAT2B Q92831 1/20 0.50
▸ KAT5 Q92993 1/20 0.50
▸ OXER1 Q8TDS5 1/20 0.48
▸ LIPG Q9Y5X9 1/20 0.46
▸ NR1H2 P55055 1/20 0.46
▸ NR1H3 Q13133 1/20 0.46
▸ CYSLTR2 Q9NS75 4/20 0.45
▸ CYSLTR1 Q9Y271 4/20 0.45
▸ MMP2 P08253 2/20 0.44
▸ F7 P08709 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057930 1.00 BID (0.50) BIDMCL1PPARABCL2L1BAK1
SCHEMBL16058319 1.00 BID (0.50) BIDMCL1PPARABCL2L1BAK1
SCHEMBL14977312 1.00 BID (0.50) BIDMCL1PPARABCL2L1BAK1
SCHEMBL14975143 1.00 BID (0.50) BIDMCL1PPARABCL2L1BAK1
SCHEMBL16057420 0.86 F7 (0.50) BIDMCL1PPARABCL2L1BAK1
SCHEMBL16056989 0.85 HDAC3 (0.42) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL16057540 0.85 SLC16A3 (0.41) OXER1CYSLTR2CYSLTR1
SCHEMBL14975444 0.84 BID (0.50) BIDMCL1BCL2L1BAK1CYSLTR2
SCHEMBL16058352 0.84 BID (0.50) BIDMCL1BCL2L1BAK1CYSLTR2
SCHEMBL14975362 0.84 BID (0.50) BIDMCL1BCL2L1BAK1CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 BID 1720/4885MCL1 2993/4885PPARA 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback